Costco members will soon have access to weight-loss shots at a major discount

Costco is partnering with Novo Nordisk to offer its members access to popular GLP-1 medications, including Wegovy and Ozempic, at a discounted rate of $499 for a four-week supply through its Member Prescription Program. This strategic collaboration enhances Costco's member value proposition and pharmacy segment, while expanding Novo Nordisk's direct market penetration for these high-demand drugs, potentially impacting pharmaceutical distribution models and competition within the weight-loss and diabetes treatment sectors.

Analysis

Costco members will soon have access to weight-loss shots at a major discount The cost will reportedly be $499 for a four-week supply Costco’s latest perk could help shrink members’ waistlines, while having less of an impact on their wallets. The big-box retailer is partnering with Novo Nordisk to give members access to popular GLP-1 medications such as Wegovy and Ozempic at half price. "Our collaboration with Costco is another step forward by Novo Nordisk in making real Wegovy® and Ozempic® easier to access and afford – right where people already shop," Dave Moore, Executive Vice President, U.S. Operations of Novo Nordisk Inc., said in a statement sent to Fox Business. "By partnering with one of the country’s most trusted retailers, we are meeting people where they are and connecting them to real, FDA-approved medicines in our premium pen devices with our $499 self-pay offer. Everyone deserves care that’s simple, reliable, and within reach – and we’re proud to lead the way in helping make that a reality," Moore added. NEW COSTCO HOURS TAKE EFFECT: WHAT IT MEANS FOR MEMBERS The medication will be available through the Costco Member Prescription Program and will cost $499 for a four-week supply, according to reports. Novo Nordisk already offers the medication at that price to self-paying patients through its website. To get the discount, members must have a prescription and pay out of pocket, according to People. The outlet noted that Novo Nordisk said Costco Executive Members and Costco Citibank Visa cardholders will get an additional discount on the medications, subject to applicable terms. NOVO NORDISK TO SELL WEIGHT-LOSS DRUG FOR $499 TO ELIGIBLE CUSTOMERS Novo Nordisk is a Danish healthcare company that develops treatments for an array of illnesses, including diabetes and obesity drugs. The company's website states that it produces half of the world’s insulin. Notably, it produces Wegovy and Ozempic, both of which are FDA-approved semaglutide medications. Ozempic’s main ingredient, known as semaglutide, is in Wegovy, which was approved by the FDA in 2021 to treat obesity. Despite gaining popularity for its impact on weight-loss, Ozempic is approved to treat people with Type 2 diabetes, while Wegovy is approved for weight management. GET FOX BUSINESS ON THE GO BY CLICKING HERE Glucagon-like peptide-1 (GLP-1) is a hormone that impacts glucose and is regulated by GLP-1 receptors. Ozempic’s website notes that it "acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1." The medication also lowers fasting blood glucose by stimulating insulin secretion, according to Ozempic’s website. Additionally, the company notes its medication can lower glucagon secretion and causes a delay in gastric emptying. Fox Business reached out to Costco for comment. The strategic partnership between Costco (COST) and Novo Nordisk (NVO) to offer GLP-1 medications, Wegovy and Ozempic, at a discounted price of $499 for a four-week supply represents a significant development for both companies. For Costco, this initiative materially enhances its membership value proposition and strengthens its pharmacy segment, leveraging the high consumer demand for weight-loss drugs to drive store traffic and member loyalty. This is reflected in the positive sentiment score of 0.7 for the retailer. For Novo Nordisk, this collaboration opens a powerful new direct-to-consumer distribution channel through a trusted, high-volume retailer, a move its executive described as making the drugs 'easier to access and afford.' While the price point is consistent with what Novo Nordisk already offers directly, the Costco channel vastly expands market reach and convenience, justifying the highly positive 0.8 sentiment score for NVO. This arrangement could serve as a disruptive model in the pharmaceutical space, potentially bypassing traditional intermediaries for the growing self-pay patient segment. The minor involvement of Citibank (C) and Visa (V) through potential additional cardholder discounts is an ancillary detail and not a material event for those entities, as indicated by their neutral sentiment scores.

Key Decisions for Investors

• Investors should view this partnership as a positive catalyst for Costco, as it strengthens its membership moat and is likely to drive incremental, high-margin pharmacy revenue and associated in-store sales.
• For Novo Nordisk investors, this direct-to-consumer channel expansion is a clear bullish signal, poised to accelerate sales volume growth for its key GLP-1 franchise by directly accessing Costco's large and loyal member base.
• The success of this model should be monitored as a key indicator of shifting pharmaceutical distribution strategies, which could create competitive pressure on traditional retail pharmacies and pharmacy benefit managers (PBMs).